MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lenox, R. H.
Right arrow Articles by Ehrlich, Y. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lenox, R. H.
Right arrow Articles by Ehrlich, Y. H.

Alpha 2-adrenergic receptor-mediated regulation of adenylate cyclase in the intact human platelet. Evidence for a receptor reserve

RH Lenox, J Ellis, D Van Riper and YH Ehrlich

The alpha 2-adrenergic receptor on the human platelet is known to mediate the inhibition of adenylate cyclase activity. A comparison of the binding and response properties of intact cells revealed that the full agonists norepinephrine and epinephrine inhibit cyclic AMP accumulation with apparently higher affinity than they exhibit in inhibiting the binding of [3H]yohimbine. Additionally, Hill coefficients of the occupancy curves of the agonists were less than unity, suggesting the presence of a heterogeneous receptor population in intact platelets under conditions that permit robust inhibition of cyclic AMP accumulation. The partial agonist clonidine was found to possess the same affinity in the binding assay as in the response assay. These data are consistent with the presence of a receptor reserve in this system, a suggestion that was confirmed in experiments utilizing the irreversible alpha 2 antagonist phenoxybenzamine. The IC50 (100 nM) derived from the blockade of [3H]yohimbine binding by phenoxybenzamine was significantly less than the IC50 (550 nM) for the corresponding reversal by phenoxybenzamine of the effects of norepinephrine on cyclic AMP accumulation. Further studies demonstrated a rightward shift in the dose-response curves for the inhibition by norepinephrine of cyclic AMP accumulation following pretreatment with increasing phenoxybenzamine concentration. These data consistently indicated that occupancy of approximately 10% of the alpha 2-adrenergic receptors by norepinephrine elicits a half-maximal adenylate cyclase response. The relationship of these findings to current models of receptor-effector coupling is discussed.

Volume 27, Issue 1, pp. 1-9, 01/01/1985
Copyright © 1985 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
CirculationHome page
H. Lin and D. B. Young
Opposing Effects of Plasma Epinephrine and Norepinephrine on Coronary Thrombosis In Vivo
Circulation, February 15, 1995; 91(4): 1135 - 1142.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1985 by the American Society for Pharmacology and Experimental Therapeutics